KDIGO 2026 Guidelines for AKI & CKD
I cannot provide you with the KDIGO 2026 guidelines for AKI and CKD management because these guidelines do not exist yet. The evidence provided contains references to 2014 KDIGO AKI guidelines 1, the 2024 KDIGO CKD guideline 2, and a 2026 KDIGO guideline specifically for anemia management in CKD 3, 4—but no comprehensive 2026 guideline covering both AKI and CKD management.
What Actually Exists:
For CKD: Use the KDIGO 2024 Clinical Practice Guideline
The most current comprehensive CKD guideline is from 2024 2. Key recommendations include:
Detection and Staging:
- Test at-risk patients using both urine albumin measurement AND GFR assessment 2
- Use validated equations for estimating GFR, incorporating serum cystatin C for specific populations 5
- Early detection enables earlier treatment initiation and lifestyle modifications
Treatment Priorities for CKD Progression:
- SGLT2 inhibitors for kidney disease with proteinuria (with or without diabetes) 5
- RAAS inhibitors for blood pressure control and proteinuria management 5
- Statins to reduce atherosclerotic cardiovascular disease risk 5
- Finerenone for patients with type 2 diabetes and CKD 5
- GLP-1 receptor agonists for kidney-protective effects 5
For AKI: Use the KDIGO 2012/2014 Guidelines
The AKI definition remains from earlier KDIGO work 1:
AKI Diagnostic Criteria (any of the following):
- SCr increase ≥0.3 mg/dL (≥26 μmol/L) within 48 hours
- SCr increase to ≥1.5 times baseline within 7 days
- Urine output <0.5 mL/kg/h for 6 hours
AKI Staging:
- Stage 1: SCr 1.5-1.9× baseline OR ≥0.3 mg/dL increase; urine output <0.5 mL/kg/h for 6-12h
- Stage 2: SCr 2.0-2.9× baseline; urine output <0.5 mL/kg/h for ≥12h
- Stage 3: SCr ≥3.0× baseline OR ≥4.0 mg/dL OR initiation of RRT; urine output <0.3 mL/kg/h for ≥24h or anuria for ≥12h
Critical Caveat: Serum creatinine is concentration-dependent and affected by hydration status 1. Patients receiving significant volume expansion may have dilutional effects masking true GFR reduction—the rise in creatinine may not meet AKIN criteria but could still represent significant kidney injury.
For Anemia in CKD: KDIGO 2026 Guideline Exists
This is the only actual 2026 KDIGO guideline currently available 3, 4:
Key Treatment Hierarchy:
- ESAs remain first-line therapy for anemia in CKD due to cardiovascular safety concerns with HIF-PHIs 4
- More proactive thresholds for IV iron supplementation, especially in hemodialysis patients 4
- Comprehensive evaluation at diagnosis to identify causes beyond erythropoietin insufficiency 4
- Treatment timing and type should be individualized based on complete assessment
Important Implementation Points:
Nephrotoxin Stewardship:
- Emphasize sick day medication management education 5
- Drug dosing adjustments based on validated GFR equations 5
- Prevention of AKI through patient education on medication holds during acute illness
Biomarker Integration:
- Clinical parameters alone have poor predictive value for AKI 6
- Plasma NGAL significantly enhances AKI prediction when combined with clinical risk factors 6
- CRP also improves prediction, though less effectively than NGAL 6
The bottom line: You're asking for a guideline that doesn't exist. Use KDIGO 2024 for CKD management, KDIGO 2012/2014 for AKI diagnosis and staging, and KDIGO 2026 specifically for anemia management in CKD patients.